Market Overview:

The global antihypertensive drugs market is expected to exhibiting a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Antihypertensive drugs are therapeutic medications used for preventing, controlling and treating hypertension and high blood pressure disorders. Hypertension is the prolonged and persistent elevation in blood pressure, which can lead to cardiac stroke and aneurism. Some commonly used antihypertensive drugs include diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors and vasodilators. These drugs remove excess fluids and salts from the body and relax and widen the blood vessels. They also aid in slowing down the heartbeat and maintaining a healthy systolic blood pressure. These drugs can be administered orally or through intravenous injections and are widely used in hospitals, clinics, rehabilitation centers and ambulatory surgical centers.

Antihypertensive Drugs Market Trends:

The increasing prevalence of hypertension and cardiovascular disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is anticipated to drive the market toward growth. Due to the increasingly sedentary lifestyles and adoption of unhealthy dietary patterns, there is an alarming increase in the number of patients suffering from high blood pressure and hypertension. This has led to the widespread adoption of antihypertensive drugs for timely prevention and treatment of hypertension. In line with this, the widespread adoption of combination therapies is contributing to the growth of the market. These innovative therapies combine multiple drugs to treat several hypertensive mechanisms, resulting in reduced occurrence of cerebrovascular events and coronary issues. Additionally, the development of imidazolines, monatepil and neutral endopeptidase inhibitors are acting as other growth-inducing factors. These next-generation drugs cause minimal fatigue and dry mouth and can also aid in lowering blood pressure by inhibiting the metabolism of vasoactive peptides. Other factors, including rising healthcare expenditures of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapeutic class, type and distribution channel.

Breakup by Therapeutic Class:

• Diuretics
• ACE Inhibitors
• Calcium Channel Blockers
• Beta-adrenergic Blockers
• Vasodilators
• Others
   

Breakup by Type:

• Primary Hypertension
• Secondary Hypertension
   

Breakup by Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Sun Pharmaceutical Industries Ltd.

Report Coverage:

Key Questions Answered in This Report:

• How has the global antihypertensive drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global antihypertensive drugs market?
• What are the key regional markets?
• What is the breakup of the market based on the therapeutic class?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global antihypertensive drugs market and who are the key players?
• What is the degree of competition in the industry?